Victory Capital Management Inc. trimmed its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 106,586 shares of the insurance provider's stock after selling 2,876 shares during the quarter. Victory Capital Management Inc. owned about 0.09% of Humana worth $33,760,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also bought and sold shares of HUM. Orion Portfolio Solutions LLC lifted its position in shares of Humana by 17.3% during the 1st quarter. Orion Portfolio Solutions LLC now owns 4,299 shares of the insurance provider's stock valued at $1,490,000 after buying an additional 634 shares in the last quarter. Dorsey & Whitney Trust CO LLC lifted its position in shares of Humana by 22.1% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 983 shares of the insurance provider's stock worth $341,000 after buying an additional 178 shares in the last quarter. M&G Plc bought a new position in Humana during the first quarter valued at approximately $5,622,000. Westfield Capital Management Co. LP purchased a new position in Humana during the 1st quarter valued at approximately $294,000. Finally, Covestor Ltd increased its stake in Humana by 59.3% in the 1st quarter. Covestor Ltd now owns 387 shares of the insurance provider's stock worth $134,000 after acquiring an additional 144 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.
Humana Price Performance
Humana stock traded down $7.47 during midday trading on Friday, reaching $275.67. The company had a trading volume of 1,842,901 shares, compared to its average volume of 2,301,719. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm's fifty day simple moving average is $281.36 and its 200-day simple moving average is $331.81. The company has a market capitalization of $33.19 billion, a P/E ratio of 24.42, a P/E/G ratio of 2.17 and a beta of 0.52. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18.
Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts' consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. As a group, equities analysts anticipate that Humana Inc. will post 15.86 EPS for the current year.
Humana Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.885 dividend. The ex-dividend date is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.28%. Humana's dividend payout ratio (DPR) is 31.36%.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. UBS Group lowered their target price on Humana from $380.00 to $250.00 and set a "neutral" rating for the company in a research report on Friday, October 4th. Sanford C. Bernstein upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $308.00 target price on the stock in a report on Tuesday, October 8th. Piper Sandler downgraded Humana from an "overweight" rating to a "neutral" rating and cut their target price for the company from $392.00 to $274.00 in a research report on Thursday, October 3rd. Barclays raised their price target on Humana from $250.00 to $253.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 31st. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $395.00 target price on shares of Humana in a research report on Tuesday, October 1st. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $315.86.
Get Our Latest Research Report on Humana
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Articles
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
